AU2001275996A1 - Production of polyhydroxyalkanoates from polyols - Google Patents

Production of polyhydroxyalkanoates from polyols

Info

Publication number
AU2001275996A1
AU2001275996A1 AU2001275996A AU2001275996A AU2001275996A1 AU 2001275996 A1 AU2001275996 A1 AU 2001275996A1 AU 2001275996 A AU2001275996 A AU 2001275996A AU 2001275996 A AU2001275996 A AU 2001275996A AU 2001275996 A1 AU2001275996 A1 AU 2001275996A1
Authority
AU
Australia
Prior art keywords
diol
hydroxybutyrate
hydroxyalkanoate
organism
comonomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001275996A
Other versions
AU2001275996B2 (en
Inventor
Martha Sholl
Frank A. Skarly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ CheilJedang Corp
Original Assignee
CJ CheilJedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ CheilJedang Corp filed Critical CJ CheilJedang Corp
Priority claimed from PCT/US2001/022834 external-priority patent/WO2002008428A2/en
Publication of AU2001275996A1 publication Critical patent/AU2001275996A1/en
Application granted granted Critical
Publication of AU2001275996B2 publication Critical patent/AU2001275996B2/en
Assigned to CJ RESEARCH CENTER LLC reassignment CJ RESEARCH CENTER LLC Request for Assignment Assignors: METABOLIX, INC.
Assigned to CJ CHEILJEDANG CORPORATION reassignment CJ CHEILJEDANG CORPORATION Request for Assignment Assignors: CJ RESEARCH CENTER LLC
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Description

PRODUCTION OF POLYHYDROXYALKANOATES FROM
POLYOLS
Cross Reference to Related Applications Priority is claimed to U.S. Provisional Application Serial No.
60/219,995 filed on July 21, 2000.
Background of the Invention This invention is generally in the field of production of polyhydroxyalkanoates (PHAs) by genetic engineering of bacteria. Synthesis of PHA polymers containing the monomer 4- hydroxybutyrate (4HB), such as poly(3-hydroxybutyrate-co-4- hydroxybutyrate) (PHB4HB) (Doi, 1995, Macromol. Symp. 98:585-99) or 4- hydroxyvalerate and 4-hydroxyhexanoate containing PHA polyesters have been described, for example, in Nalentin et al., 1992, Appl. Microbiol. Biotechnol. 36:507-14 and Nalentin et al., 1994, Appl. Microbiol. Biotechnol. 40:710-16. Production of PHB4HB, for example, has been accomplished by feeding glucose and 4HB or a substrate that is converted to 4- hydroxybutyrate to Ralstonia eutropha (Kunioka, et al., 1988, Polym. Commun. 29:174; Doi, et al., 1990, Int. J. Biol. Macromol. 12:106; Νakamura, et al., 1992, Macromolecules 25:423), to Alcaligenes lotus (Hiramitsu, et al., 1993, Biotechnol. Lett. 15:461), to Pseudomonas acidovorans (Kimura, et al., 1992, Biotechnol. Lett. 14:445), and to Comamonas acidovorans (Saito & Doi, 1994, Int. J. Biol. Macromol. 16:18). Substrates that are converted to 4HB include 1,4-butanediol, 1,6-hexanediol, 1,8-octanediol, 1,10-decanediol, 1,12-dodecanediol and garnma- butyrolactone. The PHB4HB copolymers can be produced with a range of monomer compositions which provide a range of polymer properties. In particular, as the amount of 4HB increases above 15 wt.%, the melting temperature (Tm) decreases below 130 °C and the elongation to break increases above 400 % (Saito, et al., 1996, Polym. Int. 39:169).
It would be highly advantageous, however, to develop more cost effective ways of producing PHAs containing 4HB by biological systems. For economic production of PHA, several factors are critical, including substrate costs, fermentation time, and efficiency of downstream processing. A general characteristic of the wild type PHA-producing bacteria is that their growth rate is low, they are often difficult to break open and their amenity to genetic engineering is limited. Therefore, it would be desirable to develop transgenic organisms that provide improved economics of PHA production.
The production of the copolymer PHB4HB in recombinant E. coli has been described (e.g., PCT WO 00/011188 by Huisman et al.; PCT WO 98/39453 by Hein et al.). A range of novel biologically produced 4HB polymers produced in recombinant E. coli have been described by Skraly and Peoples (e.g., PCT WO 99/61624). In these studies only the Huisman reference demonstrated the incorporation of small amounts of 4HB co- monomer from 1,4-butanediol. It would be highly advantageous to develop genetically engineered systems capable of the production of a range of 4HB copolymers and poly-4HB homopolymer using 1 ,4-butanediol as the source of the 4HB monomer.
It is therefore an object of the present invention to provide improved recombinant systems and methods for the production of PHAs, such as PHAs containing the 4HB monomer, using a variety of simple sugars and alcohols as substrates.
Summary of the Invention
Recombinant processes are provided whereby additional genes are introduced into E. coli which have been genetically engineered to produce PHA so that the improved strains produce PHA homopolymers and copolymers directly from diols. In preferred embodiments, PHAs containing 4-hydroxybutyrate (4HB) monomers are produced directly from 1,4- butanediol; PHAs containing 5-hydroxyvalerate (5HN) are produced from 1,5-pentanediol; PHAs containing 6-hydroxyhexanoate (6HH) are produced from 1,6-hexanediol; PHAs containing 3-hydroxypropionate (3HP) are produced from 1,3-propanediol (also called propylene glycol); PHAs containing 2-hydroxypropionate (2HP, lactate) are produced from 1,2- propanediol (propylene glycol); PHAs containing 2-hydroxyethanoate (2HE, glycolate) are produced from 1,2-ethanediol (ethylene glycol). Genes encoding these same enzyme activities can be introduced or their expression amplified in wild type PHA producers to improve the production of PHA homopolymers and copolymers directly from diol and other alcohol feedstocks. The PHA polymers are readily recovered and industrially useful as polymers or as starting materials for a range of chemical intermediates.
Brief Description of the Drawings Figure 1 illustrates the pathway from 1,4-butanediol to 4- hydroxybutyryl-CoA that is employed in one embodiment.
Detailed Description of the Invention
Processes are provided whereby additional genes are introduced into microorganisms which have been genetically engineered to produce PHA so that the improved strains produce PHA homopolymers and copolymers directly from simple alcohol and sugar substrates. These processes are based on recombinant bacteria e.g., Escherichia coli as a production organism and PHA biosynthetic genes from PHA-producing microbes such as Ralstonia eutropha or Alcaligenes latus although many other sources of PHA genes are now known (Madison & Huisman, 1999, Microbiol. & Molecular Biology Reviews, 63:21-53). Recombinant E. coli has many advantages over the wild type PHA producing organisms including ease of genetic manipulation, complete availability of the genome sequence, fast growth rate, flexibility of growth substrates and ready lysis. Organisms to be Engineered
In one embodiment, genes for the entire pathway illustrated in Figure 1 are introduced into the production organism. An organism that does not naturally produce PHAs, such as Escherichia coli, may be used. A number of recombinant E. coli PHB production systems have been described (Madison & Huisman, 1999,
Microbiology & Molecular Biology Reviews, 63:21-53). The genes encoding a diol oxidoreductase and aldehyde dehydrogenase are introduced into this host. In the case of 1,4-butanediol, the diol oxidoreductase converts the substrate to 4- hydroxybutyraldehyde, which is then converted to 4-hydroxybutyrate by the aldehyde dehydrogenase. In the case of 1,3 -propanediol, the diol oxidoreductase converts the substrate to 3-hydroxypropionaldehyde, which is then converted to 3- hydroxypropionate by the aldehyde dehydrogenase. Other diols may be treated in an analogous way. In some instances incorporation into PHA of a hydroxyacid that is two carbons shorter than the diol feedstock may occur. This is due to endogenous catabolism resembling that of the beta-oxidation pathway of fatty acid catabolism. For example, 4HB units, or both 4HB and 6HH units, may be produced in the polymer as a result of feeding 1,6-hexanediol. Optionally an exogenous acyl-CoA transferase or acyl-CoA synthetase may be included to facilitate activation of the hydroxyacid with coenzyme A. The activated monomer may then be incorporated into PHA by the action of an appropriate PHA synthase present in the production host. The enzyme activities provide a system for the synthesis in the production host of a polymer containing one or more monomer types, depending upon the diol feedstocks.
It is often very useful to synthesize copolymers containing monomers like those mentioned above and 3HB. In this case, the production host will also contain the β-ketothiolase and acetoacetyl-CoA reductase genes, the products of which convert acetyl-CoA to 3HB-CoA. Acetyl-CoA may be derived from the diol or from another carbon source such as a sugar. Both 3HB-CoA and hydroxyacyl-CoAs such as those mentioned above can be accepted by various PHA synthases such as the one expressed in the recombinant host, and therefore copolymers of PHB are synthesized by the recombinant host. Whatever the desired PHA composition, the diol can be fed to the cells either during growth or after a separate growth phase, either alone or in combination with at least one other feedstock, such as a sugar, and PHA is accumulated within the cells.
In another embodiment, a recombinant organism that naturally contains at least part of the pathway shown in Figure 1 can be used. In this embodiment one or more of the activities discussed above (diol oxidoreductase, aldehyde dehydrogenase, acyl-CoA transferase or acyl-CoA synthetase, β-ketothiolase, PHA synthase, and acetoacetyl-CoA reductase) can be derived from the endogenous machinery of the host. For example, only diol oxidoreductase and aldehyde dehydrogenase might be expressed in R. eutropha, a natural PHA-producing organism, to augment its ability to convert 1,4-butanediol to 4HB, and the natural ability of the host may be relied upon to accomplish the rest of the necessary metabolic steps. Many natural PHA-producing organisms are well-known to those skilled in the art (Braunegg et al. 1998, J Biotechnology 65:127-61). If the host is not capable of PHA production, a PHA synthase or an entire PHB biosynthetic pathway and optionally an exogenous acyl-CoA transferase or acyl-CoA synthetase may be introduced into this organism to enable PHA production. Techniques for doing this are well known in the art (for example, Dennis et al., 1998, J
Biotechnology 64: 177-86). Here also, the diol can be fed to the cells either during growth or after a separate growth phase, either alone or in combination with at least one other feedstock, such as a sugar, and PHA is accumulated within the cells. The implementation of the production of PHAs with diol feedstocks is not limited to bacteria as described in the examples. The same genes may be introduced into eukaryotic cells, including but not restricted to, yeast cells and cultured plant cells.
Genes for Utilization of Substrates
Genes and techniques for developing recombinant PHA producers suitable for use as described herein are generally known to those skilled in the art (Madison & Huisman, 1999, Microbiology and Molecular Biology Reviews, 63:21-53; PCT WO 99/14313). Because all of the genes necessary to implement the production of PHAs from feedstocks such as diols and sugars have been cloned and are available in genetically manipulatable form, any combination of plasmid-borne and integrated genes may be used, and the implementation of this pathway is therefore not restricted to the schemes outlined herein. Many different implementations will be apparent to those skilled in the art.
1,3 -Propanediol oxidoreductase (EC 1.1.1.202) is found in several species of bacteria. Often it is induced under anaerobic conditions in the presence of glycerol (Forage & Foster, 1982, J Bacteriol. 149:413-419). This enzyme catalyzes the reversible formation of 3- hydroxypropionaldehyde and other hydroxyaldehydes from the corresponding diol. Physiologically the enzyme is thought to be primarily used in diol formation, when the aldehyde is needed as an electron acceptor at the expense of NADH (Johnson & Lin, J. Bacteriol. 169:2050-54). Organisms that contain 1 ,3-propanediol oxidoreductase typically are able to convert glycerol to 1,3 -propanediol, though similar activities are found in other organisms. Bacterial species noted for the ability to convert glycerol to 1,3 -propanediol include Klebsiella pneumoniae (Streekstra et al., 1987, Arch. Microbiol. 147:268-75). Klebsiella oxytoca (Homann et al., 1990, Appl. Microbiol. Biotechnol. 33:121-26), Klebsiella planticola (Id.) and
Citrobacter freundii (Boenigk et al., 1993, Appl. Microbiol. Biotechnol. 38:453-57) although many other examples are generally known.
Aldehyde dehydrogenases are extremely common in biological systems. Probing the E. coli genome database for homology shows that this organism alone contains at least seven putative enzymes of this type. They are so numerous and varied that even attempts to classify them all are complicated (e.g. Nasiliou et al., 1999, Pharmacogenetics 9:421-34). A discussion of all of the types and physiological roles of these enzymes is beyond the scope of this discussion. The choice of an appropriate aldehyde dehydrogenase for use in metabolic engineering should be done after evaluation of the substrate specificity of several candidates. Enzyme assays such as that described in Baldoma & Aguilar (1987, J. Biol. Chem. 262:13991-6) are useful for such diagnoses.
Acyl-CoA transferases (EC 2.8.3.x) and acyl-CoA synthetases (EC 6.2.1.x) both catalyze the formation of thioesters of organic acids with coenzyme A. Acyl-CoA transferases, such as OrfZ (also called HbcT) (Sohling and Gottschalk, 1996, J. Bacteriol 178:871-80) transfer the CoA moiety from a donor such as acetyl-CoA to a free organic acid, such as a fatty acid. Acyl-CoA synthetases such as AlkK (van Beilen et al., 1992, Mol. Microbiol. 6: 3121-36) ligate free organic acid and free coenzyme A, deriving the energy for the reaction from ATP and leaving AMP and pyrophosphate as byproducts. Improvements in the Enzymes in the Pathway It may be advantageous to improve the specific activity or substrate specificity of the enzymes in the diol-to-PHA pathway described herein. For example, a specific diol may not be converted to PHA at an acceptable rate in a specific organism. Improvements ofthis nature will generally involve mutagenesis and screening; the DNA sequence(s) to be improved are subjected to one or more rounds of mutagenesis followed by an assessment of improvements made.
Mutagenesis can be implemented using any of a variety of ways known to those skilled in the art (e.g., error-prone PCR or cassette mutagenesis, passage through bacterial mutator strains, treatment with chemical mutagens), such as those described by Cadwell et al., 1992, PCR Methods and Applications 2:28-33; Erickson et al., 1993, Appl. Environ. Microbiol. 59:3858-62; Hermes et al., 1990, Proc. Natl. Acad. Sci. USA 87:696-700; Ho et al., 1989, Gene 77:51-59; Kellog et al., 1981, Science 214:1133-35; Reidhaar-Olson et al, 1988, Science 241:53-57; Stemmer, 1994, Nature 370:389-91; and Stemmer, 1994, Proc. Natl. Acad. Sci. USA 91:10747-51.
Screening for an improved diol-to-PHA pathway involves culturing a population of mutants generated as described above in such a way that cells improved in some property relating to the pathway can be selected readily. One embodiment is the selection for improved growth on the diol of interest. An organism deficient in uptake or utilization of a particular diol will not grow well with that diol as the sole carbon source. A pool of mutants can be inoculated into liquid medium or onto agar plates containing the diol as sole carbon source, along with all other nutrients necessary for growth of the organism in question, and cells able to grow may be readily isolated. Another embodiment is the selection of cells able to produce polymer when cultured in the presence of the diol. If an organism is unable to convert the diol at a significant rate to a monomer precursor that can subsequently be polymerized, plating that organism on agar containing the diol as the sole carbon source (other than carbon contained in any complex supplements added, such as yeast extract) will yield cells with little or no PHA content. Culturing a pool of mutants on such a plate can identify strains that have gained the ability to convert the diol to polymerizable intermediates. These cells will appear more opaque and white than the non-PHA-producing cells. Alternatively, another carbon source such as glucose may be added if the cells to be screened cannot synthesize polymer from that carbon source. Plates can also serve to eliminate strains that cannot grow in the conditions it presents; for example, a cell that has gained via mutagenesis the ability to produce PHA from diol, but has lost an industrially important characteristic such as the ability to grow on minimal glucose medium, will not grow on plates containing diol and glucose, especially if it cannot grow on the diol as sole carbon source. Only the cells that can produce PHA from diol and can grow on minimal glucose in this case will appear as opaque colonies. PHA can be visualized within cells, especially on plates, by methods more sensitive than visual screening of untreated colonies, such as by staining with Nile red (as in, e.g., Spiekermann et al, 1999, Arch Microbiol. 171:73-80.). Methods such as those above may be repeated for several rounds to further optimize the diol-to-PHA pathway. Methods of screening are illustrated by, but not restricted to, the aspects of the discussion above, and other useful screening procedures will be apparent to those skilled in the art. Regulation of Expression
In any of the aforementioned embodiments, it is possible to control the composition of the polymer produced by controlling the expression of the diol oxidoreductase and aldehyde dehydrogenase or by controlling the availability of the diol. The higher the activities of diol oxidoreductase and aldehyde dehydrogenase, the more activated monomer will be derived as a result of their activities, up to the point where another factor such as substrate availability or an enzyme activity downstream of these becomes limiting. Methods for modulation of gene expression (and thus enzyme activity) in various organisms are well-known to those skilled in the art. The rate of diol feed to the cultured cells can be controlled by various techniques well-known to those skilled in fermentation and cell culture. In the case of some microorganisms, some or all of the genes can be integrated into the host chromosome and some or all provided on a plasmid. In some cases, compatible plasmid systems can be used, for example, with several steps of the pathway encoded on one plasmid and the other steps encoded by a second plasmid. A combination of the two approaches may also be used.
Substrates
As discussed above, substrates that can be used to make PHAs in the context of the systems described herein include alcohols, preferably diols. Examples of suitable diols include 1,6-hexanediol, 1,5-pentanediol, 1,4- butanediol, 1,3 -propanediol, 1,2-ethanediol, and 1,2-propanediol.
These diols are nontoxic to many microorganisms, in many cases even at high concentrations. They can be superior feedstocks for fermentation as compared to organic acids, which often become toxic at low concentrations to many microorganisms. Many diols are readily available and relatively inexpensive. For example, 1,4-butanediol had a global demand of about 1 billion pounds in 1995 and is very widely used for synthetic polymer production (Morgan, Chemistry & Industry, 3 March 1997, pp. 166-8). The present invention will be further understood by reference to the following non-limiting examples. Example 1: Enzymatic Assay of Escherichia coli AldH
On the basis of its homology with other aldehyde dehydrogenases, the aldH gene was cloned by PCR from the E. coli genome. Plasmid pMS33 contains aldH under the control of the trc promoter. E. coli DH5α was transformed with pMS33 or pFS14, as a negative control. Plasmid pFS14 contains the Clostridium kluyveri 4hbD (4HB dehydrogenase) gene, as described in Sδhling and Gottschalk (1996, J Bacteriol. 178:871-80).
DH5α/pMS33 and DH5α/pFS14 were grown at 37 °C with shaking in Luria-Bertani (LB; Difco; Detroit, Mich.) broth to an optical density (600 nm) of 0.5 and subsequently induced with 1 mM isopropyl-β-D- thiogalactopyranoside (IPTG). The incubation continued for 3 hours, after which the cells were removed from the medium by centrifugation (2000 g,
10 min.), washed in 0.1 M Tris (pH 8.0), centrifuged again, and resuspended in a volume of 0.1 M Tris (pH 8.0) roughly equal to the size of the cell pellet.
Each sample was sonicated (XL sonicator, Heat Systems-Ultrasonics, Inc., Farmingdale, NY) with a microtip in 3-mL aliquots on ice for 2 min. each at a 70% cycle with a one-second interval. The lysate was spun in a microcentrifuge at 14,000 g for 10 min. and the supernatant was collected and designated crude cell extract.
The enzyme assays were conducted in a total volume of 1 mL containing 100 mM sodium glycine (pH 9.5), 1 mM 3- hydroxypropionaldehyde (3 HP A), 1 mM NAD+ or NADP+, 6 mM dithiothreitol (DTT), and a volume of crude cell extract containing 20-100 μg total protein. A baseline was established prior to adding 3 HP A, which started the reaction. The activity given by the DH5 /pFS14 extract was 0.00 U/mg when NAD+ was used and 0.03 U/mg when NADP+ was used. The activity given by the DH5α/pMS33 extract was 1.89 U/mg when NAD+ was used and 0.32 U/mg when NADP+ was used. Thus cells expressing the E. coli AldH protein gain the ability to convert 3 HP A to 3-hydroxypropionic acid with either NAD+ or NADP+ as cofactor. Construction of pFS14
The 4hbD gene was cloned by PCR using the plasmid pCK3 (Sόhling
& Gottschalk, 1996, J Bacteriol. 178:871-80) as a template. The following oligonucleotide primers were used:
5' - CTCTGAATTCAAGGAGGAAAAAATATGAAGTTATTAAAATTGGC - 3' (SEQ ID NO: 1)
(4hbD 5' Eco l)
5' - TTTCTCTGAGCTCGGGATATTTAATGATTGTAGG - 3' (SEQ ID NO:2)
(4hbD V Sacl)
The resulting PCR product was digested with EcoRI and S cl and ligated to plasmid pTrcN that had been digested with the same enzymes. pTrcN is a derivative of pTrc99a (Pharmacia; Uppsala, Sweden); the modification that distinguishes pTrcN is the removal of the Ncol restriction site by digestion with Ncol, treatment with T4 DΝA polymerase, and self-ligation. Construction of pMS33
On the basis of its homology with other aldehyde dehydrogenases, the aldH gene was cloned by PCR from the E. coli genome using the following oligonucleotide primers:
5' -GGTGGTACCTTAAGAGGAGGTTTTTATGAATTTTCATCACCTGGCTT -3'(SEQIDΝO:3) (aldH5' Acc65ϊ) 5' -GGTGCGGCCGCTCAGGCCTCCAGGCTTATCCA-3' (SEQ IDNO:4) (aldH3' Notl)
The resulting PCR product was digested with^4cc65I and Notl and ligated to pSE380 (Invitrogen; Carlsbad, CA) that had been digested with the same enzymes to form pMS33. Example 2: Growth of E. coli with 1,4-Butanediol as Sole Carbon Source
E. coli strain LS5218 (obtained from the Yale E. coli Genetic Stock Center, New Haven, Conn., as strain CGSC 6966) was transformed with either of two plasmids, pFS76 or pFS77. pFS76 contains the 4HB dehydrogenase (gbd) gene from Ralstonia eutropha, as described in Valentin et al. (1995, Eur. J. Biochem. 222:43-60). Plasmid pFS77 contains the gbd gene as well as the E. coli aldehyde dehydrogenase (aldH) gene and the Klebsiella pneumoniae 1,3 -propanediol oxidoreductase (dhaT) gene, arranged in a single operon. Both plasmids contain the trc promoter for transcription of the genes.
LS5218/pFS76 and LS5218/pFS77 were streaked onto minimal- medium plates containing 5 g/L of either 4HB (4-hydroxybutyrate, as the sodium salt) or 1,4-butanediol. The plate medium also contained, per liter: 15 g agar; 1 mmol MgSO4; 10 mg thiamine; 25.5 mmol Na2HPO ; 33.3 mmol K2HPO4; 27.2 mmol KH2PO4; 2.78 mg FeSO4-7H2O; 1.98 mg MnCl2-4H2O; 2.81 mg CoSO4-7H2O; 0.17 mg CuCl2-2H2O; 1.67 mg CaCl2-2H2O; 0.29 mg ZnSO4-7H2O; 100 μg ampicillin; and 0.1 mmol IPTG. The plates were incubated overnight at 37 °C. Both strains grew on the 4HB plate, but only LS5218/pFS77 grew on the 1,4-butanediol plate. Therefore, it was shown that the pathway consisting of the gbd, aldH, and dhaT genes is sufficient for growth of E. coli LS5218 with 1,4-butanediol as the sole carbon source.
Construction of pFS76
The gbd gene was amplified by PCR from the genome of R. eutropha HI 6 (obtained from the American Type Culture Collection, Rockville, Md., as strain ATCC 17699) using the following oligonucleotide primers: 5 ' - CCTGAATTCAGGAGGTTTTTATGGCGTTTA TCTACTATCTGACCCAC - 3 '(SEQ ID NO:5) (gbd 5' Ecom)
5' - CCTGAGCTCCTACCTGCAAGTGCTCGCCGCTC - 3' (SEQ ID NO:6) (gbd 3' Sad)
The resulting PCR product was digested with EcoRI and Sαcl and ligated to pSE380 (Invitrogen; Carlsbad, CA) that had been digested with the same enzymes to form pFS76.
Construction of pFS77 The aldH-dhaT region was removed from pMS59 by digestion with
Nhel and Hϋwdlll. Plasmid pFS76 was digested with Spel and Hwdlll. Nhel and Spel form compatible sticky ends. The aldH-dhaT 'fragment from pMS59 and the large fragment of pFS76 were ligated together to give pFS77, containing the gbd, aldH, and dhaT 'genes, all under control of the trc promoter.
Example 3: Production of PoIy(4HB) From 1,4-Butanediol
Escherichia coli strain LS5218 (CGSC 6966) was transformed with either of two plasmids, pFS30 or pMS60. pFS30 contains the Ralstonia eutropha PHA synthase (phaC) gene and the Clostridium kluyveri 4HB-CoA transferase (hbcT) gene, both under control of the trc promoter. pMS60 contains the aldH and dhaT genes along with the two genes in pFS30, all under control of the trc promoter. The objective of the experiment was to determine whether the addition of the aldH and dhαT genes would be beneficial to the conversion of 1,4-butanediol to 4HB in the PHA polymer. Each strain was grown in LB broth supplemented with 100 μg/mL ampicillin overnight at 37 °C with shaking at 250 rpm. The cells were then removed from the medium by centrifugation (2000 g, 10 min.) and resuspended in 100 mL of a medium containing, per liter: 2.5 g LB powder; 50 mmol potassium phosphate, pH 7.0; 2 g glucose; 5 g 1,4-butanediol; 100 μg ampicillin; and 0.1 mmol IPTG. These incubations were at 30 °C with shaking at 250 rpm for 25 hours. The cells from one-quarter of the volume of the flask were centrifuged as above, washed with water, centrifuged again, and lyophilized. About 20 mg of lyophilized cell mass from each flask was subjected to simultaneous extraction and butanolysis at 110 °C for 3 hours in 2 mL of a mixture containing (by volume) 90% 1-butanol and 10% concentrated hydrochloric acid, with 2 mg/mL benzoic acid added as an internal standard. The water-soluble components of the resulting mixture were removed by extraction with 3 mL water. The organic phase (1 μL at a split ratio of 1:50 at an overall flow rate of 2 mL/min) was analyzed on an SPB-1 fused silica capillary GC column (30 m; 0.32 mm ID; 0.25 μm film; Supelco; Bellefonte, PA) with the following temperature profile: 80 °C, 2 min; 10 °C per min. to 250 °C; 250 °C, 2 min. The standard used to test for the presence of 4-hydroxybutyrate units in the polymer was gamma- butyrolactone (Aldrich Chemical Co.; Milwaukee, WI).
Strain LS5218/pFS30 reached an optical density (600 nm) of 3.9 and had accumulated poly-4HB to 3.3% of the dry cell weight, while strain LS5218/pMS60 reached an optical density (600 nm) of 6.5 and had accumulated poly-4HB to 12.3% of the dry cell weight. Thus expression of the αldH and dhαT genes is sufficient to increase the ability of E. coli LS5218 to synthesize poly-4HB from 1,4-butanediol. Construction of pFS16
The plasmid pFS16 was constructed by ligating the Clostridium kluyveri orfZ (also called hbcT) PCR product to pTrcN. The orfZ gene was amplified by PCR from plasmid ρCK3 (Sδhling and Gottschalk, 1996, J. Bacteriol 178:871-80) using the following oligonucleotide primers:
5' - TCCCCTAGGATTCAGGAGGTTTTTATGGAGTGGGAA GAGATATATAAAG - 3 ' (SEQ ID NO:7) (orfZ 5' Avrll)
5' - CCTTAAGTCGACAAATTCTAAAATCTCTTTTTAAATTC - 3'
(SEQ ID NO.-8)
(orfZ SaR)
The resulting PCR product was digested with ^4vrII and Sail and ligated to pTrcN that had been digested with Xbal (which is compatible with Avrll) and Sail to form pFS 16.
Construction of pFS30
The plasmid pFS30 was derived from pFS16 by adding the Ralstonia eutropha PHA synthase (phaC) gene. The plasmid pAeT414 was digested with Xmal and Stwl so that the R. eutropha promoter and the structural phaC gene were present on one fragment. pFS16 was cut with BamHl, treated with T4 DNA polymerase to create blunt ends, then digested with rø l. The two DNA fragments thus obtained were ligated together to form pFS30. Construction of pMS59 The aldH gene was removed from pMS33 by digestion with Spel and
BgRl. Plasmid pTC42 (Skraly et al, 199%, Appl. Environ. Microbiol. 64:98- 105), which contains the Klebsiella pneumoniae dhaT gene under the control of the trc promoter, was digested with Nhel and BgRl. Spel and Nhel form compatible sticky ends. The WH-containing fragment of pMS33 and the large fragment of pTC42 were ligated together to form pMS59. Construction of pMS60
The aldH-dhaT 'region was isolated from pMS59 by digestion with Spel, followed by treatment with the Klenow fragment of DNA polymerase I and subsequent digestion with Mfel. This fragment had one blunt end and one sticky end compatible with EcoRI-generated sticky ends. pFS30 was digested with wrøl, followed by treatment with the Klenow fragment of DNA polymerase I and subsequent digestion with EcoRI. The large fragment of pFS30 and the aldH-dhaT-containing fragment of pMS59 were ligated together to form pMS60.
Example 4: Synthesis of PoIy(3HB-co-4HB) from Glucose and 1,4-Butanediol E. coli strain MBX1493 is a poly(3HB-co-4HB) producing strain with the C. kluyveri orfZ (also called hbcT) gene (Sohling & Gottschalk, 1996, J Bacteriol. 178:871-80) integrated into its chromosome. It was derived from strain MBX1335, a PHB-producing strain with thephaA,phaB, andphaC genes integrated into its chromosome. MBX1335 was itself derived from MBX820 (see PCT WO 00/011188 by Metabolix) by bacteriophage PI transduction of the phaA, phaB, and phaC genes into strain LS5218.
Strain MBX1493 was transformed with four plasmids in separate procedures: pTrcN, pTC42, pMS33, and pMS59. These plasmids contain, under control of the trc promoter, the following genes, respectively: none, dhaT 'only, aldH only, both aldH and dhαT. Each of these strains was grown in 3 mL LB supplemented with 100 μg/mL ampicillin at 37 °C with shaking overnight. A volume of 1 mL of each of these cultures was used as an inoculum into 50 mL of a medium containing, per liter: 1 mmol MgSO4; 10 mg thiamine; 25.5 mmol Na2HPO4; 33.3 mmol K2HPO4; 27.2 mmol KH2PO4; 2.78 mg FeSO4-7H2O; 1.98 mg MnCl2-4H2O; 2.81 mg CoSO4-7H2O; 0.17 mg CuCl2-2H2O; 1.67 mg CaCl2-2H2O; 0.29 mg ZnSO4-7H2O; 10 g glucose; 5 g 4-hydroxybutyrate or 10 g 1,4-butanediol; 100 μg ampicillin; 25 μg chloramphenicol; and 0.01 mmol IPTG. These cultures were incubated at 30 °C with shaking at 250 rpm for 88 hours. The cells were removed from this medium by centrifugation (2000 g, 10 min.), and they were lyophilized and analyzed for PHA content and composition by GC. Table 1 shows the composition of the polymers made by these strains and the final optical densities (600 nm) of the cultures. As shown in Table 1 , all strains produce a copolymer with a significant percentage of 4HB when fed 4HB. However, when fed 1,4- butanediol, only the pMS59-containing cells, that is, the cells expressing both aldH and dhαT, achieved a significant level of 4HB incorporation into the polymer. Thus the αldH-dhαT pathway was shown to enable the conversion of 1,4-butanediol to 4HB and not to interfere significantly with cell health or the subsequent incorporation of 4HB into a PHA. Table 1: Conversion of 1,4-butanediol to 4HB
1 Percent of total dry cell weight. ' Percent of total polymer weight.
Example 5: Production of Poly(3HP) from 1,3-Propanediol
Escherichia coli strain LS5218 (CGSC 6966) was transformed with either of two plasmids, pFS30 or pMS60. The objective of the experiment was to determine whether the addition of the aldH and dhαT genes would be beneficial to the conversion of 1,3 -propanediol to 3 HP. Each strain was grown in LB broth supplemented with 100 μg/mL ampicillin overnight at 37 °C with shaking at 250 rpm. The cells were then removed from the medium by centrifugation (2000 g, 10 min.) and resuspended in 50 mL of a medium containing, per liter: 2.5 g LB powder; 50 mmol potassium phosphate, pH 7.0; 5 g glucose; 0 or 10 g 1,3- propanediol; 100 μg ampicillin; and 0.1 mmol IPTG. These incubations were at 30 °C with shaking at 250 rpm for 25 hours. The cells were removed from the medium by centrifugation as described above, washed with water, centrifuged again, lyophilized, and analyzed for PHA content and composition by GC. The standard used to test for the presence of 3- hydroxypropionate units in the polymer was beta-propiolactone (Aldrich Chemical Co.; Milwaukee, WI). In the flasks without added 1,3 -propanediol, no PHP formation was detected; strains LS5218/pFS30 and LS5218/pMS60 reached optical densities (600 nm) of 4.6 and 8.2, respectively. In the flasks with added 1,3- propanediol, strain LS5218/pFS30 reached an optical density (600 nm) of 5.2 and did not accumulate poly-3HP to a detectable level, while strain LS5218/pMS60 reached an optical density (600 nm) of 6.6 and had accumulated poly-3HP to 5.0% of the dry cell weight. Thus expression of the aldH and dhαT genes is sufficient to increase the ability of E. coli LS5218 to synthesize poly-3HP from 1,3 -propanediol. Example 6: Synthesis of Poly(3HB-co-3HP) from Glucose and 1,3-Propanediol Strain MBX1493 was transformed with four plasmids in separate procedures: pTrcN, pTC42, pMS33, and pMS59. Each of these strains was grown in 100 mL LB supplemented with 100 μg/mL ampicillin at 37 °C with shaking overnight. The cells were decanted from each flask, and the residual liquid was retained. To each flask was then added 80 mL of a medium containing, per liter: 6.25 g LB powder; 1 mmol MgSO4; 10 mg thiamine; 25.5 mmol Na2HPO4; 33.3 mmol K2HPO4; 27.2 mmol KH2PO4; 2.78 mg FeSO4-7H2O; 1.98 mg MnCl2-4H2O; 2.81 mg CoSO4-7H2O; 0.17 mg CuCl2-2H2O; 1.67 mg CaCl2-2H2O; 0.29 mg ZnSO4-7H2O; 10 g glucose; 100 μg ampicillin; 25 μg chloramphenicol; and 0.01 mmol IPTG. These cultures were incubated at 37 °C with shaking at 250 rpm for 7 hours. To each flask was then added 20 mL of the same medium given above, except that in this medium LB was increased to 12.5 g/L, glucose was increased to 100 g/L, IPTG was increased to 0.25 mM, and 1,3 -propanediol was added at 50 g/L. Thus the final concentrations added at this stage were 2.5 g/L LB, 20 g/L glucose, 10 g/L 1,3 -propanediol, and 0.05 mM IPTG. These flasks were incubated at 30 °C for 24 hours with shaking at 250 rpm. The cells were then removed from this medium by centrifugation (2000 g, 10 min.), and they were lyophilized and analyzed for PHA content and composition by GC. Table 2 shows the composition of the polymers made by these strains and the final optical densities (600 nm) of the cultures. In the absence of 1,3 -propanediol, each strain synthesized only PHB. When fed 1,3 -propanediol, only the pMS59-containing cells, that is, the cells expressing both aldH and dhaT, achieved a significant level of 3HP incorporation into the polymer. The cells containing pMS33, or aldH alone, do accomplish 3HP incorporation, but to only a small extent. Thus the αldH- dhαT pathway was shown to enable the conversion of 1,3-propanediol to 3HP. The cells containing the dhαT gene (pTC42 and pMS59) made less total polymer when 1,3-propanediol was present, and this is most likely due to the toxicity of 3-hydroxypropionaldehyde. Increasing the ratio of αldH to dhαT expression and/or reducing 1,3-propanediol concentration should subdue this phenomenon.
1 Percent of total dry cell weight. b Percent of total polymer weight.
Example 7: Use of Acyl-CoA Synthetase for PoIy(4HB) synthesis from 1,4-Butanediol.
Strain MBX1668, which has the αldH and dhαT genes integrated into its chromosome as an operon along with the tetracycline resistance marker from TnlO, was transformed with either of two plasmids: pFS73 or pMS92. The plasmid pFS73 is the same as pFS30 described in previous examples except that the ampicillin resistance marker has been replaced with the kanamycin resistance marker from pACYC177 (GenBank Accession No. X06402). The plasmid pMS92 is derived from pFS73, the orfZ gene having been replaced with the αlkK gene from Pseudomonαs oleovorαns (van Beilen et al., 1992, Mol. Microbiol. 6:3121-36). Each of these strains was grown in 3 mL LB supplemented with 50 μg/mL kanamycin and 10 μg/mL tetracycline at 37 °C with shaking overnight. One milliliter of each culture was added as an inoculum to a 200-mL square bottle. Each bottle held 50 L of a medium containing, per liter: 0.1 g casamino acids; 5 mmol MgSO4; 10 mg thiamine; 25.5 mmol Na2HPO4; 33.3 mmol K2HPO4; 27.2 mmol KH2PO4; 2.78 mg FeSO4-7H2O; 1.98 mg MnCl2-4H2O; 2.81 mg CoSO4-7H2O; 0.17 mg CuCl2-2H2O; 1.67 mg CaCl2-2H2O; 0.29 mg ZnSO -7H2O; 10 g glucose; 10 g 1,4-butanediol; 50 μg kanamycin; and 10 μg tetracycline. These cultures were incubated at 30 °C with shaking at 250 rpm for 48 hours. The cells were then removed from this medium by centrifugation (2000 g, 10 min.), and they were lyophilized and analyzed for PHA content and composition by GC. Strain MBX1668 harboring pFS73 contained 5.8% poly(4HB) by dry weight, while MBX1668 harboring pMS92 contained 27.7% poly(4HB) by dry weight. Thus the alkK gene is an acceptable, and in this case better, substitute for the orfZ gene in the synthesis of PHAs from diols.

Claims (21)

We claim:
1. A method for producing polyhydroxyalkanoates comprising providing genetically engineered organisms which express enzymes selected from the group consisting of diol oxidoreductase, aldehyde dehydrogenase, acyl-CoA transferase, acyl-CoA synthetase, β-ketothiolase, acetoacetyl-CoA reductase, and PHA synthase, providing diols which can be converted into hydroxyalkanoate monomers by enzymes expressed by the organisms, and culturing the organisms under conditions wherein the hydroxyalkanoate monomers are polymerized to form polyhydroxyalkanoates.
2. The method of claim 1 wherein the diol is 1,6-hexanediol and the hydroxyalkanoate monomer is 6-hydroxyhexanoate.
3. The method of claim 1 wherein the diol is 1,5-pentanediol and the hydroxyalkanoate monomer is 5-hydroxyvalerate.
4. The method of claim 1 wherein the diol is 1,4-butanediol and the hydroxyalkanoate is 4-hydroxybutyrate.
5. The method of claim 1 wherein the diol is 1,3-propanediol and the hydroxyalkanoate monomer is 3 -hydroxypropionate.
6. The method of claim 1 wherein the diol is 1,2-ethanediol and the hydroxyalkanoate is 2-hydroxyethanoate.
7. The method of claim 1 wherein the diol is 1,2-propanediol and the hydroxyalkanoate is 2-hydroxypropionate.
8. A genetically engineered organism for use in the method of claim 1 comprising an organism which expresses the aldH and dhαT genes.
9. The organism of claim 8 wherein the organism is selected from the group consisting of Escherichia coli, Ralstonia eutropha, Klebsiella spp., Alcaligenes latus, Azotobacter spp., and Comamonas spp.
10. A system for making polyhydroxyalkanoates comprising an organism genetically engineered to express enzymes selected from the group consisting of a diol oxidoreductase, aldehyde dehydrogenase, acyl-CoA transferase, acyl-CoA synthetase, β-ketothiolase, acetoacetyl-CoA reductase, and PHA synthase, wherein the organism can convert diols into hydroxyalkanoate monomers which are polymerized to form polyhydroxyalkanoates.
11. A composition comprising a polyhydroxyalkanoate copolymer which includes
2-hydroxypropionate or 2-hydroxyethanoate or both, and at least one comonomer selected from the group consisting of 3- hydroxybutyrate, 4-hydroxybutyrate, 3 -hydroxypropionate, 2- hydroxybutyrate, 4-hydroxyvalerate, 5-hydroxyvalerate, 6- hydroxyhexanoate, and 3-hydroxyhexanoate, having a weight-average molecular weight (Mw) of at least 300,000.
12. The composition of example 11 where the comonomer is 3- hy dr oxybutyrate .
13. The composition of example 11 where the comonomer is 4- hydroxybutyrate.
14. The composition of example 11 where the comonomer is 3- hydroxypropionate.
15. The composition of example 11 where the comonomer is 2- hydroxybutyrate.
16. The composition of example 11 where the comonomer is 4- hydroxyvalerate.
17. The composition of example 11 where the comonomer is 5- hydroxyvalerate.
18. The composition of example 11 where the comonomer is 6- hydroxyhexanoate.
19. The composition of example 11 where the comonomer is 3- hydroxyhexanoate.
20. A method for improving a biological system for making polyhydroxyalkanoates with an organism genetically engineered to express enzymes selected from the group consisting of a diol oxidoreductase, aldehyde dehydrogenase, acyl-CoA transferase, acyl-CoA synthetase, β- ketothiolase, acetoacetyl-CoA reductase, and PHA synthase, wherein the organism can convert diols into hydroxyalkanoate monomers which are polymerized to form polyhydroxyalkanoates, the method comprising selecting for mutants with increased enzyme activities by i) introducing mutations into a specific host, and ii) screening pools of the mutants generated for increased ability to synthesize PHA from a selected diol or diols.
21. A DNA fragment encoding a diol oxidoreductase and an aldehyde dehydrogenase, wherein the expressed enzymes can produce hydroxyalkanoate monomer selected from the group consisting of 3- hydroxybutyrate, 4-hydroxybutyrate, 3 -hydroxypropionate, 2- hydroxybutyrate, 4-hydroxyvalerate, 5-hydroxyvalerate, 6- hydroxyhexanoate, 3-hydroxyhexanoate, 2-hydroxypropionate, and 2- hydroxyethanoate from diol.
AU2001275996A 2000-07-21 2001-07-20 Production of polyhydroxyalkanoates from polyols Expired AU2001275996B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21999500P 2000-07-21 2000-07-21
US60/219,995 2000-07-21
PCT/US2001/022834 WO2002008428A2 (en) 2000-07-21 2001-07-20 Production of polyhydroxyalkanoates from polyols

Publications (2)

Publication Number Publication Date
AU2001275996A1 true AU2001275996A1 (en) 2002-05-02
AU2001275996B2 AU2001275996B2 (en) 2005-08-04

Family

ID=22821601

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001275996A Expired AU2001275996B2 (en) 2000-07-21 2001-07-20 Production of polyhydroxyalkanoates from polyols
AU7599601A Pending AU7599601A (en) 2000-07-21 2001-07-20 Production of polyhydroxyalkanoates from polyols

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU7599601A Pending AU7599601A (en) 2000-07-21 2001-07-20 Production of polyhydroxyalkanoates from polyols

Country Status (8)

Country Link
US (2) US20020164729A1 (en)
EP (1) EP1305439B1 (en)
JP (1) JP4860094B2 (en)
KR (1) KR20040014389A (en)
AT (1) ATE329048T1 (en)
AU (2) AU2001275996B2 (en)
DE (1) DE60120415T2 (en)
WO (1) WO2002008428A2 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7165624B1 (en) * 1998-05-15 2007-01-23 Grinnell Corporation Early suppression fast response fire protection sprinkler
US7318833B2 (en) 2001-12-19 2008-01-15 Nmt Medical, Inc. PFO closure device with flexible thrombogenic joint and improved dislodgement resistance
US7867250B2 (en) 2001-12-19 2011-01-11 Nmt Medical, Inc. Septal occluder and associated methods
AU2003220502A1 (en) 2002-03-25 2003-10-13 Nmt Medical, Inc. Patent foramen ovale (pfo) closure clips
ES2741964T3 (en) * 2002-05-10 2020-02-12 Tepha Inc Bioabsorbable polymer containing 2-hydroxy acid monomers
EP1538994A4 (en) 2002-06-05 2008-05-07 Nmt Medical Inc Patent foramen ovale (pfo) closure device with radial and circumferential support
US20040002958A1 (en) 2002-06-26 2004-01-01 Praveen Seshadri System and method for providing notification(s)
US8071355B2 (en) 2002-09-12 2011-12-06 Metabolix, Inc. Polyhydroxyalkanoate production by coenzyme A-dependent aldehyde dehydrogenase pathways
AU2003284976A1 (en) 2002-10-25 2004-05-13 Nmt Medical, Inc. Expandable sheath tubing
US9017373B2 (en) 2002-12-09 2015-04-28 W.L. Gore & Associates, Inc. Septal closure devices
US7476521B2 (en) 2003-01-22 2009-01-13 Showa Denko K.K. Method for acyltransferase reaction using acyl coenzyme A
US7056439B2 (en) * 2003-05-06 2006-06-06 Tate & Lyle Ingredidents Americas, Inc. Process for producing 1, 3-propanediol
US8480706B2 (en) 2003-07-14 2013-07-09 W.L. Gore & Associates, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US9861346B2 (en) 2003-07-14 2018-01-09 W. L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure device with linearly elongating petals
JP4917887B2 (en) 2003-07-14 2012-04-18 ダブリュー.エル.ゴア アンド アソシエイツ,インコーポレイテッド Tubular patent foramen ovale (PFO) closure device with capture system
EP1660167B1 (en) 2003-08-19 2008-11-12 NMT Medical, Inc. Expandable sheath tubing
US20050273119A1 (en) 2003-12-09 2005-12-08 Nmt Medical, Inc. Double spiral patent foramen ovale closure clamp
WO2005092203A1 (en) 2004-03-03 2005-10-06 Nmt Medical, Inc. Delivery/recovery system for septal occluder
US20050267524A1 (en) 2004-04-09 2005-12-01 Nmt Medical, Inc. Split ends closure device
US8361110B2 (en) 2004-04-26 2013-01-29 W.L. Gore & Associates, Inc. Heart-shaped PFO closure device
JP4523939B2 (en) * 2004-04-27 2010-08-11 三井化学株式会社 Method for producing hydroxycarboxylic acids
US7842053B2 (en) 2004-05-06 2010-11-30 Nmt Medical, Inc. Double coil occluder
US8308760B2 (en) 2004-05-06 2012-11-13 W.L. Gore & Associates, Inc. Delivery systems and methods for PFO closure device with two anchors
US8257389B2 (en) 2004-05-07 2012-09-04 W.L. Gore & Associates, Inc. Catching mechanisms for tubular septal occluder
DE102004030385B4 (en) * 2004-06-23 2008-02-07 Sächsisches Institut für Angewandte Biotechnologie e.V. (SIAB) Process for the preparation of poly (3-hydroxybutyric acid-co-4-hydroxybutyric acid) (P3HB / 4HB) of defined molar composition with Delftia acidovorans P4A
CA2581677C (en) 2004-09-24 2014-07-29 Nmt Medical, Inc. Occluder device double securement system for delivery/recovery of such occluder device
WO2006102213A1 (en) 2005-03-18 2006-09-28 Nmt Medical, Inc. Catch member for pfo occluder
WO2007073566A1 (en) 2005-12-22 2007-06-28 Nmt Medical, Inc. Catch members for occluder devices
US8551135B2 (en) 2006-03-31 2013-10-08 W.L. Gore & Associates, Inc. Screw catch mechanism for PFO occluder and method of use
US8870913B2 (en) 2006-03-31 2014-10-28 W.L. Gore & Associates, Inc. Catch system with locking cap for patent foramen ovale (PFO) occluder
EP2004068B1 (en) 2006-03-31 2018-08-15 W.L. Gore & Associates, Inc. Deformable flap catch mechanism for occluder device
US8765402B2 (en) * 2006-11-21 2014-07-01 Lg Chem, Ltd. Copolymer containing 3-hydroxyalkanoate unit and lactate unit, and its manufacturing method
WO2008062995A1 (en) * 2006-11-21 2008-05-29 Lg Chem, Ltd. Copolymer comprising 4-hydroxybutyrate unit and lactate unit and its manufacturing method
KR100957773B1 (en) 2006-11-23 2010-05-12 주식회사 엘지화학 Novel Copolymer of [Poly3-hydroxypropionate-co-lactate] and Method for Preparing the Same
CA2675026A1 (en) * 2007-01-12 2008-07-24 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for enhancing tolerance for the production of organic chemicals produced by microorganisms
CN101668861A (en) 2007-03-16 2010-03-10 基因组股份公司 compositions and methods for the biosynthesis of 1,4-butanediol and its precursors
WO2008124603A1 (en) 2007-04-05 2008-10-16 Nmt Medical, Inc. Septal closure device with centering mechanism
WO2008131167A1 (en) 2007-04-18 2008-10-30 Nmt Medical, Inc. Flexible catheter system
US7947483B2 (en) * 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
WO2009045719A2 (en) * 2007-10-03 2009-04-09 President And Fellows Of Harvard College Polymeric bioplastics
US8048624B1 (en) 2007-12-04 2011-11-01 Opx Biotechnologies, Inc. Compositions and methods for 3-hydroxypropionate bio-production from biomass
US20130165967A1 (en) 2008-03-07 2013-06-27 W.L. Gore & Associates, Inc. Heart occlusion devices
US20110190513A1 (en) * 2008-07-08 2011-08-04 Lynch Michael D Methods, compositions and systems for biosynthetic bio-production of 1,4-butanediol
US20110118434A1 (en) * 2008-07-11 2011-05-19 Metabolic Explorer Method for polymerising glycolic acid with microorganisms
AU2009291825B2 (en) 2008-09-10 2016-05-05 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol
TW201042103A (en) 2008-12-23 2010-12-01 Metabolix Inc Production of non-woven materials from polyhydroxyalkanoate
WO2010118041A1 (en) 2009-04-06 2010-10-14 Metabolix, Inc. Method of improving film processing and injection molding of polyhydroxyalkanoate polymers
SI3199511T1 (en) 2009-06-04 2020-07-31 Genomatica, Inc. Process of separating components of a fermentation broth
SI3392340T1 (en) 2009-06-04 2022-05-31 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol and related methods
US8956389B2 (en) 2009-06-22 2015-02-17 W. L. Gore & Associates, Inc. Sealing device and delivery system
US20120029556A1 (en) 2009-06-22 2012-02-02 Masters Steven J Sealing device and delivery system
CN102482482A (en) 2009-06-26 2012-05-30 梅塔玻利克斯公司 Pha compositions comprising pbs and pbsa and methods for their production
MX2012003604A (en) 2009-09-27 2012-09-12 Opx Biotechnologies Inc Method for producing 3-hydroxypropionic acid and other products.
US8809027B1 (en) 2009-09-27 2014-08-19 Opx Biotechnologies, Inc. Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase
EP2488652A4 (en) 2009-10-13 2014-04-09 Genomatica Inc Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-coa, putrescine and related compounds, and methods related thereto
US8530210B2 (en) 2009-11-25 2013-09-10 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
WO2011068952A1 (en) 2009-12-02 2011-06-09 Entrigue Surgical, Inc. Devices for tongue stabilization
WO2011142865A2 (en) * 2010-02-12 2011-11-17 Gevo, Inc. Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals, and amino acids
US8445244B2 (en) 2010-02-23 2013-05-21 Genomatica, Inc. Methods for increasing product yields
US8048661B2 (en) 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
CA2825624C (en) 2011-01-27 2020-01-14 Osa Holdings, Inc. Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
WO2012142100A1 (en) 2011-04-13 2012-10-18 Metabolix, Inc. Biodegradable coextruded multilayer films
US9663791B2 (en) * 2011-04-29 2017-05-30 Cj Research Center Llc Green process for producing polyhydroxyalkanoates and chemicals using a renewable feedstock
EP2702091B1 (en) 2011-04-29 2019-02-13 CJ CheilJedang Corporation Process for latex production by melt emulsification
US9770232B2 (en) 2011-08-12 2017-09-26 W. L. Gore & Associates, Inc. Heart occlusion devices
CN111705028A (en) 2012-06-04 2020-09-25 基因组股份公司 Microorganisms and methods for making 4-hydroxybutyrate, 1, 4-butanediol, and related compounds
EP2855584A1 (en) 2012-06-05 2015-04-08 Metabolix, Inc. Biobased rubber modified biodegradable polymer blends
WO2014026162A1 (en) 2012-08-10 2014-02-13 Opx Biotechnologies, Inc. Microorganisms and methods for the production of fatty acids and fatty acid derived products
WO2014028943A1 (en) 2012-08-17 2014-02-20 Metabolix, Inc. Biobased rubber modifiers for polymer blends
US10828019B2 (en) 2013-01-18 2020-11-10 W.L. Gore & Associates, Inc. Sealing device and delivery system
CA2905602A1 (en) 2013-03-15 2014-09-18 Sarah M. Hoyt Flash evaporation for product purification and recovery
US9447438B2 (en) 2013-03-15 2016-09-20 Cargill, Incorporated Acetyl-coA carboxylases
EP3004225A1 (en) 2013-05-30 2016-04-13 Metabolix, Inc. Recyclate blends
JP6603658B2 (en) 2013-07-19 2019-11-06 カーギル インコーポレイテッド Microorganisms and methods for the production of fatty acids and fatty acid derivatives
US11408013B2 (en) 2013-07-19 2022-08-09 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US9808230B2 (en) 2014-06-06 2017-11-07 W. L. Gore & Associates, Inc. Sealing device and delivery system
EP2993228B1 (en) 2014-09-02 2019-10-09 Cargill, Incorporated Production of fatty acid esters
WO2016053741A1 (en) 2014-10-01 2016-04-07 Cryosa, Llc Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
US11091632B2 (en) 2015-11-17 2021-08-17 Cj Cheiljedang Corporation Polymer blends with controllable biodegradation rates
WO2018144701A2 (en) 2017-02-02 2018-08-09 Cargill Incorporated Genetically modified cells that produce c6-c10 fatty acid derivatives
US11535873B2 (en) 2017-09-07 2022-12-27 The Governing Council Of The University Of Toronto Production of glycolate from ethylene glycol and related microbial engineering
KR102519456B1 (en) * 2018-03-15 2023-04-06 주식회사 엘지화학 Method for preparing poly(3-hydroxypropionate-b-lactate) block copolymer by using microorganisms

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1642111A1 (en) * 1965-04-20 1971-12-30 Ethicon Inc Surgical sutures and process for their manufacture
US3579549A (en) * 1967-09-29 1971-05-18 Nat Starch Chem Corp Acyl derivatives of the condensation polymers of alpha-hydroxy-propionic acid with beta-hydroxybutyric acid and/or beta-hydroxypropionic acid
CS277545B6 (en) * 1991-05-15 1993-03-17 Farmaceuticka Fakulta Uk Process for preparing hydroxy carboxylic acid oligoesters
JPH0616790A (en) * 1991-08-13 1994-01-25 Toyobo Co Ltd Aliphatic polyester and its production
JP3408557B2 (en) * 1992-06-11 2003-05-19 三井化学株式会社 Vehicle mounted lamp and manufacturing method thereof
US5294469A (en) * 1992-06-17 1994-03-15 Mitsui Toatsu Chemicals, Incorporated Industrial woven fabric and composite sheet comprising same
JPH06304253A (en) * 1993-04-23 1994-11-01 Mitsui Toatsu Chem Inc Injection cylinder
JPH08226016A (en) * 1995-02-20 1996-09-03 Mitsubishi Rayon Co Ltd Polylactic acid fiber and its production
AU2324097A (en) 1997-03-03 1998-09-22 Monsanto Company Methods for the biosynthesis of polyesters
US6156852A (en) 1997-04-21 2000-12-05 Monsanto Company Hydroxy-terminated polyhydroxyalkanoates
ATE323152T1 (en) 1997-09-19 2006-04-15 Metabolix Inc BIOLOGICAL SYSTEMS FOR THE PRODUCTION OF POLYHYDROXYALKANOATE POLYMERS THAT CONTAIN 4-HYDROXY ACID
ATE483023T1 (en) * 1998-05-22 2010-10-15 Metabolix Inc POLYHYDROXYALKANOOATBIOPOLYMERS
MXPA01001111A (en) 1998-08-04 2002-04-24 Metabolix Inc Polyhydroxyalkanoate production from polyols.
JP4623829B2 (en) * 1998-08-18 2011-02-02 メタボリックス,インコーポレイテッド Production of polyhydroxyalkanoates by transgenic microorganisms

Similar Documents

Publication Publication Date Title
US8741624B2 (en) Production of polyhydroxyalkanoates from polyols
AU2001275996A1 (en) Production of polyhydroxyalkanoates from polyols
AU753132B2 (en) Transgenic microbial polyhydroxyalkanoate producers
JP5042407B2 (en) Production of polyhydroxyalkanoates from polyols.
EP2376622B1 (en) Green process and compositions for producing poly(5hv) and 5 carbon chemicals
US5811272A (en) Method for controlling molecular weight of polyhydroxyalkanoates
EP2267133B1 (en) Method for making poly(3-hydroxyproprionate)
Heinrich et al. From waste to plastic: synthesis of poly (3-hydroxypropionate) in Shimwellia blattae
JP2008029218A (en) Method for producing copolymerized polyester by using microorganism having lowered enzymatic activity
JP2008086238A (en) Method for producing polyhydroxyalkanoate
JPWO2008090873A1 (en) Process for producing polyhydroxyalkanoate
EP1700909B1 (en) Transgenic microbial polyhydroxyalkanoate producers
JP2009225775A (en) Method of producing polyhydroxyalkanoic acid